AAV8-mediated gene therapy targeting the liver effectively normalized peripheral oxysterol levels in a mouse model of hereditary spastic paraplegia type 5 (SPG5). However, brain oxysterol levels remained partially corrected, indicating that successful SPG5 treatment requires a gene therapy approach that also targets the central nervous system.